We are live on ! Find out more
IOVA icon

Iovance Biotherapeutics
IOVA

252 hedge funds and large institutions have $4.58B invested in Iovance Biotherapeutics in 2020 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 83 increasing their positions, 91 reducing their positions, and 51 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% more call options, than puts

Call options by funds: $52.7M | Put options by funds: $26.5M

18% more capital invested

Capital invested by funds: $3.88B → $4.58B (+$704M)

0% more funds holding in top 10

Funds holding in top 10: 9 → 9 (0)

0.67% less ownership

Funds ownership: 96.25% → 95.58% (-0.67%)

9% less repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 91

10% less first-time investments, than exits

New positions opened: 46 | Existing positions closed: 51

2% less funds holding

Funds holding: 257 → 252 (-5)

Holders
252
Holders Change
-5
Holders Change %
-1.95%
% of All Funds
5.08%
Holding in Top 10
9
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.18%
New
46
Increased
83
Reduced
91
Closed
51
Calls
$52.7M
Puts
$26.5M
Net Calls
+$26.2M
Net Calls Change
-$19.2M

Top Buyers

1
AIM
ARK Investment Management
Florida
+$112M
2
Franklin Resources
Franklin Resources
California
+$41.6M
3
NAMA
Nikko Asset Management Americas
New York
+$23.5M
4
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group
Japan
+$23.3M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$13.4M

Top Sellers

1
PA
Perceptive Advisors
New York
-$52.8M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$30M
3
ACA
Avoro Capital Advisors
New York
-$25.3M
4
EAM
Eagle Asset Management
Florida
-$19.8M
5
Goldman Sachs
Goldman Sachs
New York
-$18.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
RCAMU
26
Rothschild & Co Asset Management US
Connecticut
$29.9M -$1.67M -54,597 -6%
Goldman Sachs
27
Goldman Sachs
New York
$27M -$18.8M -612,174 -43%
APM
28
Avidity Partners Management
Texas
$26.3M +$1.85M +60,453 +8%
Susquehanna International Group
29
Susquehanna International Group
Pennsylvania
$24.9M +$7.8M +254,452 +51%
RHJA
30
Rice Hall James & Associates
California
$24.4M +$1.84M +59,933 +9%
Brown Advisory
31
Brown Advisory
Maryland
$23.8M +$618K +20,155 +3%
New York State Common Retirement Fund
32
New York State Common Retirement Fund
New York
$23M +$175K +5,716 +0.8%
JP Morgan Chase
33
JP Morgan Chase
New York
$22.7M +$2.36M +77,093 +12%
CS
34
Candriam SCA
Luxembourg
$22.6M -$2.22M -72,575 -10%
Northern Trust
35
Northern Trust
Illinois
$22.4M -$390K -12,731 -2%
Wellington Management Group
36
Wellington Management Group
Massachusetts
$21.3M -$65.1K -2,122 -0.3%
Charles Schwab
37
Charles Schwab
California
$21M +$410K +13,383 +2%
FFM
38
Fairmount Funds Management
Pennsylvania
$19.6M -$215K -7,000 -1%
GTC
39
Ghost Tree Capital
New York
$18.9M -$153K -5,000 -0.9%
N
40
Nuveen
North Carolina
$18.9M +$562K +18,327 +3%
QF
41
QVT Financial
New York
$18.9M -$2.2M -71,757 -11%
NIP
42
Nicholas Investment Partners
California
$16.7M +$12.9M +422,298 +500%
HRCM
43
Hood River Capital Management
Florida
$16.4M -$1.55M -50,447 -9%
Point72 Asset Management
44
Point72 Asset Management
Connecticut
$14.6M -$30M -978,173 -69%
Balyasny Asset Management
45
Balyasny Asset Management
Illinois
$14.4M +$13.4M +437,864 New
AG
46
Artal Group
Luxembourg
$13.2M -$3.07M -100,000 -20%
NHAS
47
Novo Holdings A/S
Denmark
$12.7M +$11.8M +384,938 New
PHS
48
PFM Health Sciences
California
$12.6M +$11.7M +381,990 New
MP
49
Mangrove Partners
Connecticut
$12.5M +$9.67M +315,465 +495%
PCM
50
Peregrine Capital Management
Minnesota
$12.2M -$1.08M -35,333 -9%
1
2
3 4 5

IOVA Hedge Fund Activity: Q3 2020 in Review

252 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q3 2020, worth a combined $4.58B — up 18% from $3.88B a quarter earlier.

Sellers outnumbered buyers: 51 funds closed out of IOVA and 46 opened new positions — a net loss of 5 holders — while 91 trimmed existing stakes and 83 added.

The largest buyer was ARK Investment Management, adding an estimated $112M. The largest seller was Perceptive Advisors, cutting an estimated $52.8M.

  • 252 institutional investors held Iovance Biotherapeutics (IOVA) as of Q3 2020, down from 257 in Q2 2020.
  • Funds reported $4.58B of Iovance Biotherapeutics stock for Q3 2020, up 18% quarter-over-quarter.
  • 46 funds opened new Iovance Biotherapeutics positions in Q3 2020 and 51 closed out, a net change of -5 holders.
  • The largest Iovance Biotherapeutics buyer in Q3 2020 was ARK Investment Management, an estimated $112M added.
  • The largest Iovance Biotherapeutics seller in Q3 2020 was Perceptive Advisors, an estimated $52.8M sold.

Based on aggregated 13F filings for Q3 2020.